Maker of $34,000-a-vial drug to pay $100 million for allegedly preventing competition

Drug company Mallinckrodt Pharmaceuticals has agreed to pay US$100 million ($140m) to settle a lawsuit alleging that a company it acquired in 2014 engaged in anti-competitive behavior to preserve its monopoly on a $34,000-a-vial infantile…